Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2003

View Archived Issues

Abgenix and Chugai enter antibody therapeutics agreement

Daiichi selects compound from Pharmacopeia collaboration for preclinical development

GlycoDesign regains rights to Core 2 inhibitors

Sidmak Laboratories to change name to Pliva

New data on the anticancer efficacy of the nitrosourea derivative aranoza

Pfizer claims new 5-HT2C receptor modulators and their use in sexual disorders

Boehringer Ingelheim presents novel thrombin inhibitors

Ferring researchers identify new oxytocin agonists

New series of 5-HT6/5-HT7 ligands discovered at Sigma-Tau

Antibacterial agents discovered in joint research by Essential Therapeutics and Pliva

Novel antiherpesvirus agents in early development at GSK

Schering presents new VEGF inhibitors

New PDE5 inhibitors identified by Lilly Icos team

Research term extended in 3DP thrombin collaboration

IND cleared for NCX-1000

Japanese marketing approval sought for Glivec for GIST indication

AES-14 granted fast track status for oral mucositis associated with cancer chemotherapy

Japanese marketing application for E-7155 withdrawn

Baxter proposes Advate as brand name for rAHF-PFM

Revimid granted fast track designation for relapsed or refractory multiple myeloma

Phase III study initiated for HL-10 in ALI/ARDS

Myriad Genetics discovers DEP1 gene for depression

Cell Genesys refocuses resource investment

MS-325 phase III program completes enrollment

Nuvelo begins trading this week

Novel cytotoxic metabolite isolated from marine bacterium

MIT details the rational design of LMWHs with improved properties

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.